The study focuses on glucocerebrosidase, commonly abbreviated as GCase, an enzyme encoded by the GBA gene. GCase is located primarily inside lysosomes, the cell’s recycling compartments, where it helps break down specific fatty molecules known as glucosylceramides. Variants in GBA can reduce the enzyme’s efficiency and are among the most common genetic risk factors for Parkinson’s disease. Some variants cause Gaucher disease, a lysosomal storage disorder, while others produce subtler biochemical changes that increase Parkinson’s susceptibility without necessarily causing Gaucher disease.

Parkinson’s disease is also characterized by the accumulation of α-synuclein, a neuronal protein that can assemble into abnormal structures and contribute to Lewy bodies and Lewy neurites. However, α-synuclein is not a single, chemically uniform molecule. It exists in multiple “proteoforms,” meaning molecular variants created by differences in processing, chemical modification, truncation, aggregation state or interactions with other cellular components. These forms may behave differently in neurons, and distinguishing them could help explain why some types of α-synuclein are more toxic or more strongly associated with disease progression.

Morella and colleagues investigated these mechanisms in human brains collected after death from people with Parkinson’s disease linked to GBA alterations, people with idiopathic Parkinson’s disease, and comparison groups. The use of post-mortem tissue is crucial because it allows researchers to examine the molecular environment in the affected organ itself rather than relying only on blood, cerebrospinal fluid, cultured cells or experimental animals. At the same time, brain tissue collected after death presents analytical challenges, including differences in disease duration, medication history, tissue preservation, brain region and the extent of neuronal loss.

The central feature of the research is quantitative biochemical profiling. Rather than simply determining whether GCase or α-synuclein is present, this approach aims to measure how much enzymatic activity remains and which molecular forms of α-synuclein are present. Measuring GCase activity is particularly important because enzyme abundance alone does not necessarily indicate function. A neuron may contain detectable GCase protein while the enzyme is improperly folded, trapped in the wrong cellular compartment, chemically modified or otherwise less active.

The investigators’ examination of α-synuclein proteoforms adds another layer to the analysis. Standard laboratory tests can detect total α-synuclein, but total protein measurements may conceal biologically meaningful differences. For example, soluble α-synuclein, phosphorylated species, truncated fragments and aggregated forms may have distinct effects on synaptic function, cellular transport and lysosomal degradation. A detailed profile can therefore reveal whether GCase impairment is associated with a particular molecular signature rather than with a simple increase in the overall amount of α-synuclein.

The connection between GCase and α-synuclein is thought to operate in both directions. Reduced lysosomal GCase activity may interfere with the clearance of α-synuclein, allowing damaging species to accumulate. Conversely, α-synuclein aggregates may disrupt lysosomal trafficking or prevent GCase from reaching the compartment where it normally functions. This creates a potentially self-reinforcing cycle in which impaired cellular recycling promotes protein accumulation, while protein pathology further weakens the recycling system.

Comparing GBA-related Parkinson’s disease with idiopathic Parkinson’s disease is especially valuable because it can separate mechanisms that are specific to genetic risk from those shared across the broader Parkinson’s spectrum. If the two groups show similar biochemical patterns, that would support the idea that lysosomal dysfunction is a common pathway in Parkinson’s disease, even when no GBA mutation is identified. If they show distinct patterns, those differences could help explain variations in age of onset, clinical progression or treatment response and could guide the development of more targeted therapies.

The findings also have potential implications for drug development. Several experimental strategies are designed to increase GCase activity, improve its delivery to lysosomes, stabilize the enzyme or correct its trafficking. Other approaches aim to reduce harmful α-synuclein species or enhance their clearance. Quantitative measurements from human brain tissue can help determine whether these treatments are affecting the intended molecular targets. They may also help researchers identify biomarkers that reflect treatment response in living patients, although translating post-mortem biochemical signatures into clinical tests will require further validation.

By placing enzyme function and α-synuclein diversity in the same analytical framework, the study underscores a broader shift in Parkinson’s research. The disease is increasingly understood not as a single disorder with one uniform molecular cause, but as a collection of overlapping biological pathways that can converge on neuronal degeneration. Human-brain profiling cannot by itself establish causation, and post-mortem studies cannot fully capture the sequence of events that occurred during life. Yet by mapping the biochemical terrain with greater precision, this work may help reveal which molecular changes are drivers, which are consequences and which could serve as practical targets for the next generation of Parkinson’s therapies.

Subject of Research: Quantitative biochemical profiling of GCase activity and α-synuclein proteoforms in post-mortem human brains from GBA-related and idiopathic Parkinson’s disease.

Article Title: Quantitative biochemical profiling of GCase activity and α-synuclein proteoforms in post-mortem human brains from GBA-related and idiopathic Parkinson’s disease.

Article References: Morella, M.L., Teneketzi, M., Ferraro, F. et al. “Quantitative biochemical profiling of GCase activity and α-synuclein proteoforms in post-mortem human brains from GBA-related and idiopathic Parkinson’s disease.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01488-4

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01488-4

Keywords: Parkinson’s disease, GBA, glucocerebrosidase, GCase, α-synuclein, proteoforms, lysosomes, neurodegeneration, post-mortem human brain, biochemical profiling

The team focused on AD model mice carrying human APP/PSEN1 mutations and a fluorescent mitophagy sensor (mt-Keima). This reporter shifts optical properties depending on mitochondrial conditions, allowing investigators to distinguish mitochondria residing in acidic lysosomal environments from those that remain neutral. Over time, neurons in these animals accumulated large clusters of both acidic and neutral mitochondria within neuronal processes.

These accumulations formed “mitochondrial plaques” (MPs), a pathological architecture distinct from classical amyloid deposits. The authors propose that MPs arise from two connected problems: abnormal mitochondrial buildup and a delayed attempt by the lysosomal system to recruit those organelles for degradation. In other words, the cell appears to summon lysosomes too late to prevent the formation of persistent mitochondrial masses.

Crucially, the study shows that even when lysosomes are recruited, clearance remains incomplete. Impaired lysosomal function interferes with the final steps of mitophagy, trapping mitochondria in a state of partial processing. As a result, both neutral mitochondria (not fully delivered or processed) and acidic mitochondria (attempting degradation) accumulate together inside the MPs.

The researchers also examined whether this phenomenon depends on amyloid pathology. MPs often co-developed with amyloid plaques to form mixed lesions, but the mitochondrial structures could also appear independently at early disease stages. That timing supports a causal role for mitochondrial quality-control failure rather than a purely downstream effect of amyloid deposition.

To test generality, the team detected mitochondrial plaques in the 5xFAD AD model, strengthening the link between the mechanism and AD-like genetic stress. Finally, they extended the findings to human biology by identifying corresponding MPs in postmortem Alzheimer’s disease brains, indicating that the phenomenon is not restricted to mouse models.

Together, the work establishes mitochondrial plaques as a new pathological entity and implicates lysosomal dysfunction as a key bottleneck in mitophagy during Alzheimer’s disease. By providing direct in vivo evidence of how mitochondria can organize when clearance fails, the study adds a mechanistic target for future therapeutic strategies aimed at restoring mitochondrial quality control.

Subject of Research: Alzheimer’s disease pathology; mitophagy; lysosomal dysfunction; mitochondrial accumulation.

Article Title: Mitochondrial accumulation and lysosomal dysfunction result in mitochondrial plaques in Alzheimer’s disease.

Article References: Dan, X., Croteau, D.L., Liu, W. et al. Mitochondrial accumulation and lysosomal dysfunction result in mitochondrial plaques in Alzheimer’s disease. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02390-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02390-1

Keywords: mitophagy reporter; mitochondrial plaques; lysosomal dysfunction; neuronal processes; amyloid; Alzheimer’s disease

At the heart of this investigation is Dnajc6, a protein traditionally recognized for its role in clathrin-mediated endocytosis. Mutations in the gene encoding Dnajc6, specifically those causing truncated protein variants, have long been implicated in familial forms of Parkinson’s disease, but the precise mechanisms by which they contribute to neuronal death remained elusive. This study elucidates that truncation mutants of Dnajc6 disrupt lysosomal homeostasis, a critical cellular degradation pathway responsible for clearing misfolded proteins and maintaining cellular integrity.

Lysosomes serve as the cell’s recycling centers, degrading macromolecules and damaged organelles via enzymatic processes which are vital for neuronal survival. The research demonstrates that the Dnajc6 truncation mutant impairs lysosomal function, leading to an accumulation of dysfunctional lysosomes and subsequently a failure to adequately degrade pathogenic forms of α-synuclein. The buildup of α-synuclein aggregates within neurons is a pathological signature in Parkinson’s disease, contributing to the formation of Lewy bodies and cellular toxicity.

The importance of α-synuclein in the context of neurodegeneration cannot be overstated. Although α-synuclein is a normal presynaptic protein involved in synaptic transmission regulation, pathogenic mutations or post-translational modifications induce its misfolding and aggregation. The study reveals that lysosomal deficiency, precipitated by the Dnajc6 truncation mutant, triggers an upregulation of pathogenic α-synuclein species. These toxic oligomers and fibrils disrupt neuronal function and promote apoptotic pathways particularly in dopaminergic neurons of the substantia nigra pars compacta, the brain region critically affected in Parkinson’s disease.

The utilization of PARK19 knockin mice—a genetically engineered model harboring the human equivalently truncated Dnajc6—allowed the research team to faithfully recapitulate the cellular and molecular pathology observed in sporadic and familial Parkinson’s cases. These knockin mice showcased progressive motor deficits, dopaminergic neuron loss, and widespread α-synuclein pathology, establishing a direct causal link between the mutant Dnajc6 and Parkinsonian neurodegeneration.

In-depth biochemical analyses within this study uncovered that lysosomal enzyme activities, particularly those of cathepsins necessary for α-synuclein degradation, were markedly diminished. This enzymatic insufficiency stems from altered lysosomal biogenesis and trafficking caused by defective Dnajc6-mediated endocytic processes. Impaired endocytosis, therefore, disrupts not only synaptic vesicle recycling but also critical lysosomal maintenance pathways, underscoring the multifaceted repercussions of the mutant protein.

One particularly illuminating aspect of the research is the demonstration that lysosomal deficits lead to compensatory cellular stress responses. Neurons expressing the mutant Dnajc6 exhibit upregulated markers of autophagy, oxidative stress, and inflammatory signaling pathways. However, these protective responses eventually falter, illustrating the neurotoxic threshold reached in the substantia nigra that culminates in cell death.

This study’s implications extend to therapeutic strategies aimed at boosting lysosomal function or enhancing α-synuclein clearance. Modulating autophagy-lysosome pathways may serve as a promising intervention to halt or slow neurodegeneration in Parkinson’s disease patients harboring mutations in endocytic machinery components. Furthermore, the PARK19 knockin mouse model represents a valuable platform for preclinical evaluation of such therapeutic agents.

Adding another layer of nuance, the research team identified alterations in dopaminergic synaptic architecture in mutant mice. Synaptic vesicle cycling defects were evident, consistent with Dnajc6’s canonical role, which may exacerbate neuronal vulnerability by impairing neurotransmitter release and intracellular signaling dynamics. This synaptic dysfunction likely synergizes with lysosomal insufficiency to accelerate neurodegeneration.

Moreover, the study highlights how the interplay between genetic mutations and lysosomal pathways can shape distinct Parkinson’s disease phenotypes. This mechanistic clarity helps refine our understanding of disease heterogeneity and underscores the importance of personalized medicine approaches, tailoring treatments according to specific genetic and molecular profiles.

Importantly, the paper’s findings challenge the previous notion that endocytic mutations primarily affect synaptic function. Instead, it positions lysosomal deficiency and α-synuclein pathology at the epicenter of mutant Dnajc6-induced neurodegeneration, potentially revising current paradigms regarding the molecular underpinnings of Parkinson’s disease.

The potential translational impacts of this research are significant. By defining molecular checkpoints where the mutant Dnajc6 alters lysosomal function, researchers are better equipped to develop biomarker assays for early detection and to design targeted molecules that rectify these defects. This work also encourages longitudinal studies to investigate disease progression in patients with PARK19 mutations, correlating clinical symptoms with biomarkers of lysosomal health.

With Parkinson’s disease affecting millions worldwide and currently lacking disease-modifying treatments, insights from studies like this provide much-needed hope. The delineation of molecular cascades triggered by Dnajc6 truncation mutants offers a new lens through which the pathobiology of Parkinson’s can be viewed and addressed.

Future research avenues may include deeper exploration of the cross-talk between lysosomal pathways and other neurodegenerative processes such as mitochondrial dysfunction and neuroinflammation. Understanding these complex interactions could yield multifactorial therapeutic strategies with enhanced efficacy.

In sum, the study by Wang, Chen, Chiu, and colleagues marks a pivotal advance in neurodegenerative research, emphasizing the critical role of lysosomal integrity in preventing pathological α-synuclein accumulation and preserving dopaminergic neuron viability. The PARK19 knockin mouse emerges as an indispensable tool not only to unravel Parkinson’s disease mechanisms but also to forge the path toward innovative therapeutic interventions.

Subject of Research:
The study focuses on the role of the PARK19 truncation mutant Dnajc6 in lysosomal deficiency, the resulting upregulation of pathologic α-synuclein, and the neurodegeneration of substantia nigra dopaminergic neurons, using PARK19 knockin mouse models.

Article Title:
PARK19 truncation mutant Dnajc6 causes lysosomal deficiency-induced upregulation of pathologic α-synuclein and neurodegeneration of substantia nigra dopaminergic cells in PARK19 knockin mice.

Article References:
Wang, HL., Chen, YL., Chiu, TJ. et al. PARK19 truncation mutant Dnajc6 causes lysosomal deficiency-induced upregulation of pathologic α-synuclein and neurodegeneration of substantia nigra dopaminergic cells in PARK19 knockin mice. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01317-8

Image Credits: AI Generated

The crux of Parkinson’s disease pathology involves the misfolding and aggregation of α-Synuclein, a presynaptic neuronal protein implicated in synaptic dysfunction and neurodegeneration. While the accumulation of toxic α-Synuclein species in the brain has long been identified as a hallmark of the disease, the precise pathways connecting this proteinopathy to cognitive impairment have remained elusive. The current study pioneers the understanding of how α-Synuclein fosters lysosomal deficits, a crucial cellular waste disposal system, and how TREM2 functions within this context.

TREM2, a receptor predominantly expressed on microglia, represents a key player in immune surveillance and phagocytic clearance within the central nervous system. Previous research has documented TREM2’s role in Alzheimer’s disease, but its involvement in Parkinson’s disease-related cognitive dysfunction marks a novel area of investigation. By interrogating the impact of TREM2 deficiency on α-Synuclein pathology, Zhu and colleagues provide compelling evidence for TREM2’s protective function against lysosomal impairment.

Lysosomes serve as the cellular waste disposers, responsible for degrading and recycling damaged proteins and organelles. Dysfunctional lysosomal pathways are increasingly recognized as central contributors to neurodegeneration, as they hinder effective clearance of toxic protein aggregates, allowing pathological species to accumulate and propagate. This study elegantly demonstrates that TREM2 deficiency aggravates α-Synuclein-induced lysosomal malfunction, disrupting neuronal homeostasis and accelerating cognitive decline.

Utilizing advanced molecular biology techniques and sophisticated in vivo models mimicking Parkinson’s disease pathology, the research team meticulously quantified the extent of lysosomal disruption in the presence and absence of functional TREM2. Their findings reveal a marked exacerbation of lysosomal deficits when TREM2 is deficient, underscoring the receptor’s critical role in maintaining lysosomal integrity amid α-Synuclein stress.

Furthermore, the investigation delves into the downstream cellular consequences of impaired lysosomal function, highlighting increased oxidative stress, neuroinflammation, and synaptic damage—key pathological features that culminate in cognitive deterioration. The interplay between TREM2 signaling and these neurodegenerative cascades suggests that enhancing TREM2 function could mitigate multiple facets of disease progression.

The study also explores the molecular signaling pathways modulated by TREM2 under conditions of α-Synuclein overload. Activation of TREM2 triggers intracellular cascades that boost microglial phagocytic capacity and promote lysosomal biogenesis. Loss of TREM2 impairs these protective responses, tipping the balance towards neurotoxicity. This mechanistic insight has profound implications for developing microglia-targeted therapies aiming to restore lysosomal competence.

Cognitive impairment in Parkinson’s disease, often overshadowed by the more prominent motor symptoms, profoundly diminishes quality of life. The identification of TREM2’s pivotal role offers hope for therapeutic interventions specifically addressing the cognitive domain. Enhancing TREM2 activity or mimicking its downstream effects could constitute innovative strategies to preserve cognitive function in patients.

In light of these findings, the authors propose a model in which TREM2 deficiency creates a vicious cycle: α-Synuclein accumulation impairs lysosomal function, diminishing the ability of microglia to clear pathological proteins, which in turn fosters further α-Synuclein aggregation and neurodegeneration. Interrupting this cycle by restoring TREM2 function may represent a promising therapeutic avenue.

The implications of this research extend beyond Parkinson’s disease. Given the shared mechanisms of protein aggregation and lysosomal dysfunction across various neurodegenerative diseases, understanding TREM2’s role could inform broader neuroprotective strategies. It opens new avenues for biomarker development, diagnostic imaging, and precision medicine tailored to microglial genetic profiles.

From a translational perspective, pharmacological agents or gene therapies designed to potentiate TREM2 signaling are now poised for rigorous preclinical evaluation. The detailed mechanistic insights provided by Zhu et al. offer a roadmap to target microglial lysosomal pathways and potentially delay or reverse cognitive decline.

Importantly, the study employs cutting-edge imaging and biochemical assays to monitor lysosomal activity and α-Synuclein dynamics in real time, allowing for a nuanced understanding of temporal disease progression. This technological advancement enhances the reliability of data and paves the way for future longitudinal studies in patients.

While this research marks a significant leap forward, the authors emphasize the need for further investigation into how TREM2 interacts with other cellular pathways contributing to neurodegeneration. Identifying potential compensatory mechanisms and understanding intercellular crosstalk will be crucial to fully harness TREM2’s therapeutic potential.

The robust experimental design, including the use of both genetic knockout models and human patient-derived cells, strengthens the validity of the findings. Such comprehensive approaches underscore the pivotal role of TREM2 in maintaining lysosomal function and cognitive integrity within the Parkinsonian brain.

As the neurological community considers this new data, it is clear that targeting microglial biology and lysosomal health addresses a fundamental disease axis. This study catalyzes a paradigm shift, advocating for combined therapeutic approaches that modulate immune and proteostatic pathways simultaneously.

In conclusion, Zhu and colleagues have unraveled a critical piece of the Parkinson’s disease puzzle by demonstrating that TREM2 deficiency exacerbates cognitive impairment through the aggravation of α-Synuclein-induced lysosomal dysfunction. Their insightful work not only enlightens disease pathogenesis but also charts promising paths for innovative therapies aimed at combating neurodegeneration and preserving cognitive function in afflicted individuals.

Subject of Research: The role of TREM2 deficiency in exacerbating cognitive impairment via lysosomal dysfunction induced by α-Synuclein in Parkinson’s disease.

Article Title: TREM2 deficiency exacerbates cognitive impairment by aggravating α-Synuclein-induced lysosomal dysfunction in Parkinson’s disease.

Article References:
Zhu, B., Feng, J., Liang, X. et al. TREM2 deficiency exacerbates cognitive impairment by aggravating α-Synuclein-induced lysosomal dysfunction in Parkinson’s disease. Cell Death Discov. 11, 243 (2025). https://doi.org/10.1038/s41420-025-02538-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02538-1